Biopharma Dealmaking Quarterly Statistics, Q1 2013

A look at the financing, M&A, and alliance activity January-March 2013

Biopharma financing reached $4.6 billion in Q1 2013, exceeding Q4 2012’s $4.2 billion total, mostly through follow-on public offerings, which made up 47% of the total funding. Conversely, M&A was on the decline with 18 completed transactions together valued at $4.8 billion, the lowest quarter since 2009. The $5.5 billion potential deal value aggregate for alliances more than doubled from the previous quarter, mainly due to Biogen Idec’s $3.25 billion buy of Elan's share of multiple sclerosis drug Tysabri.

Biopharma financing had a strong start in 2013; the first quarter – with 86 biopharma financings bringing in $4.6 billion – already exceeding Q4 2012, last year’s strongest quarter, which did $4.2 billion. Follow-on public offerings accounted for nearly half of the total funding; more than a quarter of the 25 FOPOs (9 deals) were completed by cancer drug developers, which accounted for over half the FOPO volume. Onyx Pharmaceuticals Inc. had the largest, netting $352 million from its eighth follow-on public offering [See Deal] since its 1996 IPO. [See Deal] Onyx sold 4.4 million shares for $81.50 each in the biggest offering for the company to date. (Its last FOPO in 2009 netted $311 million through the sale of stock/debt [See Deal].) Onyx will use the money to continue developing Phase III carfilzomib (multiple myeloma) and Phase Ib/II oprozomib (hematologic malignancies), as well as for the global commercialization of Krypolis (carfilzomib injection), which was approved by the FDA in mid-2012 for multiple myeloma patients that have already been treated with two other therapies, yet show signs of disease progression. (See Also see "Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?" - In Vivo, 19 March, 2013..) Other oncology-focused companies also completed FOPOs, including Ariad Pharmaceuticals Inc. ($310 million), [See Deal]Pharmacyclics Inc. ($201 million), [See Deal] and, in its first FOPO since going public last year, Tesaro Inc. ($92 million). [See Deal][See Deal] (See Also see "Flush With Cash, Tesaro Advances Rolapitant Toward NDA" - Pink Sheet, 8 March, 2013..)

Other companies that exceeded the $100-million mark with their offerings were RNAi therapeutics developer Alnylam Pharmaceuticals Inc. ($174 million)...

Welcome to In Vivo

Create an account to read this article

More from Deal-Making

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Deals Shaping The Industry, June 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.